Next Article in Journal
Ultrasound for Drug Synthesis: A Green Approach
Next Article in Special Issue
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Previous Article in Journal
Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Simple Analysis of Sumatriptan and its Application in Bioequivalence Study
Previous Article in Special Issue
Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
Open AccessReview

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
*
Author to whom correspondence should be addressed.
This paper is dedicated to the 80th birthday of Prof. Horst Kessler.
Pharmaceuticals 2020, 13(2), 22; https://doi.org/10.3390/ph13020022
Received: 20 December 2019 / Revised: 14 January 2020 / Accepted: 16 January 2020 / Published: 30 January 2020
This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials. View Full-Text
Keywords: radiolabelled peptides; positron emission tomography; peptide receptor radiotherapy; oncology; metabolic stability; labelling strategies radiolabelled peptides; positron emission tomography; peptide receptor radiotherapy; oncology; metabolic stability; labelling strategies
Show Figures

Figure 1

MDPI and ACS Style

Rangger, C.; Haubner, R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals 2020, 13, 22. https://doi.org/10.3390/ph13020022

AMA Style

Rangger C, Haubner R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals. 2020; 13(2):22. https://doi.org/10.3390/ph13020022

Chicago/Turabian Style

Rangger, Christine; Haubner, Roland. 2020. "Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology" Pharmaceuticals 13, no. 2: 22. https://doi.org/10.3390/ph13020022

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop